Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genta withdraws Genasense NDA

Executive Summary

Genta is withdrawing its NDA for melanoma therapy Genasense, the company said May 13. The firm is requesting a meeting with FDA; co-developer Aventis plans to participate. FDA's Oncologic Drugs Advisory Committee voted 12 to 4 that Genta's pivotal trial for Genasense (oblimersen) did not show a "real effect" on progression-free survival (1"The Pink Sheet" May 10, 2004, p. 9)...

You may also be interested in...

Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.

Genta/Aventis Genasense appears to have a "real effect" on response rates in metastatic melanoma patients but not on progression-free survival or survival, FDA's Oncologic Drugs Advisory Committee concluded at its May 3 meeting

Piramal Profits As It Sheds DRG To Clarivate For $950m

An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.

QUOTED. 20 January 2020. Henrik Berggren.

San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts